本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301126 证券简称：达嘉维康 公告编号：2025-067 湖南达嘉维康医药产业股份有限公司 关于 2025 年前三季度利润分配预案的公告 三、现金分红方案合理性说明 特别提示： 1、公司 2025 年前三季度利润分配预案为：以公司 2025 年 9 月 30 日的总股 本 205,403,200 股为基数向全体股东每 10 股派发现金 0.22 元人民币（含税），共 计派发现金 4,518,870.40 元（含税），剩余未分配利润结转至下一年。 2、公司现金分红方案不涉及《深圳证券交易所创业板股票上市规则》第 9.4 条相关规定的可能被实施其他风险警示情形。 一、审议程序 公司于 2025 年 10 月 24 日召开的第四届董事会第十七次会议审议通过了《关 于 2025 年前三季度利润分配预案的议案》。本次利润分配预案尚需提交公司股东 会审议。 二、利润分配预案的基本情况 根据公司 2025 年前三季度财务报表（数据均未经审计），公司 2025 年前三 季度实现归属于上市公司股东的净利润 5,097 ...

达嘉维康公告，第三季度营收为14.22亿元，同比增长2.79%；净利润为420.38万元，下降8.94%。前三 季度营收为41.3亿元，同比增长3.69%；净利润为509.74万元，下降86.02%。 ...

湖南达嘉维康医药产业股份有限公司 2025 年第三季度报告 湖南达嘉维康医药产业股份有限公司 2025 年第三季度报告 2025-065 【2025-10-28】 湖南达嘉维康医药产业股份有限公司 2025 年第三季度报告 证券代码：301126 证券简称：达嘉维康 公告编号：2025-065 湖南达嘉维康医药产业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 2 湖南达嘉维康医药产业股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比上 | | ...

Core Insights - The pharmaceutical commercial sector experienced a decline of 1.0% on October 24, with Jianfa Zhixin leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Market Performance - The following companies showed varied performance in the pharmaceutical commercial sector: - Huaren Health (301408) closed at 13.17, up 0.46% with a trading volume of 44,500 shares and a turnover of 58.44 million yuan [1] - Runda Medical (603108) closed at 14.76, up 0.20% with a trading volume of 64,400 shares and a turnover of 95.39 million yuan [1] - Jianfa Zhixin (301584) led the decline, closing at 35.66, down 4.14% with a trading volume of 341,300 shares and a turnover of 1.289 billion yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 259 million yuan from institutional investors, while retail investors contributed a net inflow of 248 million yuan [2] - The following companies had notable capital flows: - Shanghai Pharmaceutical (601607) had a net inflow of 6.9169 million yuan from institutional investors [3] - Baiyang Pharmaceutical (301015) experienced a net inflow of 6.5687 million yuan from institutional investors [3] - Runda Medical (603108) had a net inflow of 3.8868 million yuan from retail investors [3]

Group 1 - The company, Dajia Weikang (301126), reported that as of October 20, 2025, the number of shareholders is 164,000 [1]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-063 湖南达嘉维康医药产业股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）为满足公司全资 子公司及控股子公司日常生产经营和业务发展资金需要，保证公司业务顺利开展， 公司于 2025 年 4 月 17 日、2025 年 5 月 12 日分别召开的第四届董事会第十四次会 议及 2024 年年度股东大会审议通过《关于 2025 年度担保额度预计的议案》，同意 公司 2025 年度为公司全资子公司及控股子公司提供担保，担保额度预计不超过 30 亿 元。具体内容详见公司于 2025 年 4 月 21 日在巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于 2025 年度担保额度预计的公告》（公告编号：2025-026）。 4、法定代表人：王毅清 5、成立日期：2004 年 6 月 1 日 6、经营范围：许可项目：药品生产（不含中药饮片的蒸、炒、炙、煅等炮制技术 的应用及中 ...

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

Core Viewpoint - As of October 10, 2025, the number of shareholders for Dajia Weikang (301126) is reported to be 15,931 [1] Company Summary - Dajia Weikang has engaged with investors through an interactive platform, providing updates on shareholder numbers [1] - The company is actively communicating with its investors, indicating a focus on transparency and shareholder engagement [1]

Core Insights - The pharmaceutical commercial sector saw a slight increase of 0.17% on October 10, with Guofa Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Guofa Co., Ltd. (600538) closed at 5.85, up 4.28% with a trading volume of 178,800 shares and a transaction value of 103 million yuan [1] - Other notable gainers included Dajia Weikang (301126) up 1.89%, Yingte Group (000411) up 1.77%, and Liuyao Group (603368) up 1.75% [1] - Conversely, the sector also experienced declines, with Saily Medical (603716) down 4.51% and Jianfa Zhixin (301584) down 4.01% [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 161 million yuan from institutional investors, while retail investors saw a net inflow of 214 million yuan [2] - The data indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 27.32 million yuan from institutional investors, while it faced a net outflow of 32.58 million yuan from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 4.95 million yuan from institutional investors, but also faced outflows from speculative funds [3] - Guofa Co., Ltd. (600538) had a net inflow of 4.07 million yuan from institutional investors, indicating some level of interest despite the overall outflow trend [3]